Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) presented data on opioid prescribing patterns among fibromyalgia patients at the 2026 American Society of Clinical Psychopharmacology Annual Meeting held May 26-29 in Miami Beach, Florida.

The retrospective analysis examined three years of closed claims data from Symphony Health, focusing on 261,776 U.S. adults with fibromyalgia during the period from April 2023 to March 2024. The study population had a mean age of 52.3 years and was predominantly female at 92.1%.

The data showed that 40.2% of patients with commercial or Medicare Advantage insurance received at least one opioid prescription, with tramadol being the most prescribed at 13.7%, followed by oxycodone at 13.1%. Among Medicaid patients, 38.8% were prescribed opioids, with oxycodone leading at 15.7% and tramadol at 11.1%.

Opioid use was highest among older patients, with 43.1% of those aged 61-65 years receiving prescriptions. The study found that 19.1% of commercial or Medicare Advantage patients and 20.4% of Medicaid patients used both opioids and benzodiazepines concurrently.

The company commercially launched TONMYA in November 2025, which it describes as the first new fibromyalgia treatment approved by the FDA in over 15 years. TONMYA received FDA approval in August 2025 for treating fibromyalgia in adults.

"The discrepancy between real-world practice and evidence-based recommendations reveals a gap in knowledge and an urgent need to educate health care prescribers," said Seth Lederman, Chief Executive Officer of Tonix Pharmaceuticals, according to the company's press release.